Sanofi and Innate Pharma expand collaboration natural killer Cell therapeutics in oncology
- Sanofi receives exclusive license for B7H3 ANKET from InnateTM program and options for two additional destinations; After candidate selection, Sanofi will be responsible for all development, manufacturing and commercialization
Paris, December 192022 Sanofi SNY and Innate Pharma SA IPHIPHA announced today an extension of their collaboration whereby Sanofi licenses a Natural Killer (NK) Cell Engager program targeting B7H3 from Innate’s ANKETTM (Antibody-based NK Cell Engager Therapeutics) platform. Sanofi will also have the option to add up to two additional ANKETTM Goals. After candidate selection, Sanofi will be responsible for all development, manufacturing and commercialization. Innate and Sanofi signed a premiere NK cell agger cooperation in 2016 for the generation and evaluation of up to two bispecific NK cell aggers currently being evaluated by Sanofi’s R&D team, with one of these molecules already in clinical trials.
.
Valeria Fantin, Ph.D.
Global Head of Oncology Research at Sanofi
“At Sanofi, we are explore the potential of NK cells for cancer immunotherapy, a key pillar of our oncology strategy. Our relationship with innate is in line with our commitment to work with promising French companies and supports our quest to develop a diverse portfolio of next-generation NK cell engagers, maximum synergistic with Sanofis allogeneic NK cell platformartificially produced lymphokines that stimulate NK cells, and growing immuno-oncology pipeline. As leading global company with We are proud to partner with our roots in France to support the French healthcare ecosystem.”
Yannis Morel, Ph.D.
Executive Vice President, Product Portfolio Strategy and Business Development at Innate Pharma
“Building on the success of our existing collaboration to hematological targetsWe are excited to expand and strengthen our partnership with Sanofi on NK Cell Engagers with the addition of up to three new…
[ad_2]
Source story
